Literature DB >> 28668574

Heterologous prime-boost immunization of Newcastle disease virus vectored vaccines protected broiler chickens against highly pathogenic avian influenza and Newcastle disease viruses.

Shin-Hee Kim1, Siba K Samal2.   

Abstract

Avian Influenza virus (AIV) is an important pathogen for both human and animal health. There is a great need to develop a safe and effective vaccine for AI infections in the field. Live-attenuated Newcastle disease virus (NDV) vectored AI vaccines have shown to be effective, but preexisting antibodies to the vaccine vector can affect the protective efficacy of the vaccine in the field. To improve the efficacy of AI vaccine, we generated a novel vectored vaccine by using a chimeric NDV vector that is serologically distant from NDV. In this study, the protective efficacy of our vaccines was evaluated by using H5N1 highly pathogenic avian influenza virus (HPAIV) strain A/Vietnam/1203/2004, a prototype strain for vaccine development. The vaccine viruses were three chimeric NDVs expressing the hemagglutinin (HA) protein in combination with the neuraminidase (NA) protein, matrix 1 protein, or nonstructural 1 protein. Comparison of their protective efficacy between a single and prime-boost immunizations indicated that prime immunization of 1-day-old SPF chicks with our vaccine viruses followed by boosting with the conventional NDV vector strain LaSota expressing the HA protein provided complete protection of chickens against mortality, clinical signs and virus shedding. Further verification of our heterologous prime-boost immunization using commercial broiler chickens suggested that a sequential immunization of chickens with chimeric NDV vector expressing the HA and NA proteins following the boost with NDV vector expressing the HA protein can be a promising strategy for the field vaccination against HPAIVs and against highly virulent NDVs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avian influenza virus; Newcastle disease virus; Vectored vaccine

Mesh:

Substances:

Year:  2017        PMID: 28668574     DOI: 10.1016/j.vaccine.2017.06.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Prime-boost vaccination strategy against avian influenza and Newcastle disease viruses reduces shedding of the challenge viruses.

Authors:  Nermeen M Ismail; Ayman H El-Deeb; Mohamed M Emara; Hoda I Tawfik; Nabil Abdel Wanis; Hussein A Hussein
Journal:  Virusdisease       Date:  2018-06-26

Review 2.  Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.

Authors:  Julia P C Fulber; Amine A Kamen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

Review 3.  Challenge for One Health: Co-Circulation of Zoonotic H5N1 and H9N2 Avian Influenza Viruses in Egypt.

Authors:  Shin-Hee Kim
Journal:  Viruses       Date:  2018-03-09       Impact factor: 5.048

4.  Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle Disease Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI Viruses.

Authors:  Yeonwoo Cho; Barisha Lamichhane; Abdou Nagy; Ishita Roy Chowdhury; Siba K Samal; Shin-Hee Kim
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

Review 5.  Innovation in Newcastle Disease Virus Vectored Avian Influenza Vaccines.

Authors:  Shin-Hee Kim; Siba K Samal
Journal:  Viruses       Date:  2019-03-26       Impact factor: 5.048

6.  MicroRNA expression profiles from HEK293 cells expressing H5N1 avian influenza virus non-structural protein 1.

Authors:  Hanwei Jiao; Zonglin Zheng; Xuehong Shuai; Li Wu; Jixuan Chen; Yichen Luo; Yu Zhao; Hongjun Wang; Qingzhou Huang
Journal:  Innate Immun       Date:  2019-02       Impact factor: 2.680

Review 7.  Avian Orthoavulavirus Type-1 as Vaccine Vector against Respiratory Viral Pathogens in Animal and Human.

Authors:  Julianne Vilela; Mohammed A Rohaim; Muhammad Munir
Journal:  Vaccines (Basel)       Date:  2022-02-08

8.  Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Authors:  Vinoth K Manoharan; Sunil K Khattar; Celia C LaBranche; David C Montefiori; Siba K Samal
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.